ReviewInternational journal of endocrinology2026
The Role of Lipid Disorders in Cardiovascular Mortality Among Saudis: A Review Perspective.
Review in International journal of endocrinology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Cardiovascular diseases (CVD) are the main cause of death worldwide and in Saudi Arabia, accounting for about 31% of all deaths globally and 45% of deaths in the Kingdom. The aim of this review was to review the epidemiology, pathophysiology, and management of lipid disorders (mainly dyslipidemia) which are major contributors to CVD in Saudi Arabia. The unique risk profile of the Saudi population with a high prevalence of dyslipidemia (especially low high-density lipoprotein cholesterol [HDL-C] and high triglycerides), in addition to the genetic factors, urbanization, sedentary lifestyle, and change in diet to a western style has been described. National surveys showed prevalence rates of dyslipidemia > 50% in adults and high prevalence in adolescents with high regional and gender differences. Low HDL-C was the most common and important lipid abnormality, which was significantly related to all-cause and CVD mortality and independently predicts adverse outcomes. This review summarizes the limits of the current treatment strategy that mainly focuses on LDL-C lowering and shows the need for the development of new therapies targeting HDL-C and triglycerides. The public health implications include an increasing economic burden, the need for early screening, culture-adapted prevention programs, and integration of genetic risk prediction. Large-scale epidemiological studies, national registries, and personalized medicine approaches are needed to fill the gaps in knowledge and optimize management. Implementing population-based programs is a must to decrease the burden of CVD and improve the outcome in Saudi Arabia which may be an example for other countries experiencing the same epidemiological transition.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.